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Abstract 
Background: Despite standard treatment for epithelial ovarian cancer (EOC), that involves cytoreductive surgery 
followed by platinum-based chemotherapy, and initial high response rates to these, up to 80 % of patients experience 
relapses with a median progression-free survival of 12–18 months. There remains an urgent need for novel targeted 
therapies to improve clinical outcomes in ovarian cancer. Of the many targeted therapies currently under evalua-
tion, the most promising strategies developed thus far are antiangiogenic agents and Poly(ADP-ribose) polymerase 
(PARP) inhibitors. Particularly, PARP inhibitors are active in cells that have impaired repair of DNA by the homologous 
recombination (HR) pathway. Cells with mutated breast related cancer antigens (BRCA) function have HR deficiency, 
which is also present in a significant proportion of non-BRCA-mutated ovarian cancer (“BRCAness” ovarian cancer). 
The prevalence of germline BRCA mutations in EOC has historically been estimated to be around 10–15 %. However, 
recent reports suggest that this may be a gross underestimate, especially in women with high-grade serous ovarian 
cancer (HGSOC).
Main body of the abstract: The emergence of the DNA repair pathway as a rational target in various cancers led 
to the development of the PARP inhibitors. The concept of tumor-selective synthetic lethality heralded the begin-
ning of an eventful decade, culminating in the approval by regulatory authorities both in Europe as a maintenance 
therapy and in the United States treatment for advanced recurrent disease of the first oral PARP inhibitor, olaparib, for 
the treatment of BRCA-mutated ovarian cancer patients. Other PARP inhibitors are clearly effective in this disease and, 
within the next years, the results of ongoing randomized trials will clarify their respective roles.
Conclusion: This review will discuss the different PARP inhibitors in development and the potential use of this 
class of agents in the future. Moreover, combination strategies involving PARP inhibitors are likely to receive increas-
ing attention. The utility of PARP inhibitors combined with cytotoxic chemotherapy is of doubtful value, because of 
enhanced toxicity of this combination; while, more promising strategies include the combination with antiangiogenic 
agents, or with inhibitors of the P13K/AKT pathway and new generation of immunotherapy.
Keywords: Epithelial ovarian cancer, Target therapy, Poly-ADP-ribose polymerase inhibitor (PARPi), Breast related 
cancer antigens (BRCA)
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Background
Epithelial ovarian cancer (EOC) accounts for 90 % of all 
ovarian cancers (OC) and typically presents in post-men-
opausal women [1].
In terms of incidence, it is the second most common 
malignant gynecological disease, the sixth most common 
cancer and the seventh most common cause of cancer 
death in women. Particularly, EOC is the most common 
cause of death from gynecological malignancy [2, 3].
Standard treatments for EOC involves cytoreductive 
surgery followed by platinum-based chemotherapy. For 
high-grade serous ovarian cancer (HGSOC), the most 
prevalent and aggressive form of EOC, relapse is nearly 
the norm because of the development of resistance, 
although approximately 80 % of patients initially respond 
to treatment [4, 5].
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According to the response to systemic therapy, EOC can 
be divided in: platinum-refractory, if there is a progression 
within 1  month or stable disease (SD) during first-line 
therapy; platinum-resistant, if there is a response dur-
ing therapy and a relapse within 6 months. Nevertheless 
recurrent EOC may be chemo-sensitive to platinum and 
therefore patients can be still treated with platinum-based 
chemotherapy; these are patients platinum-sensitive, if 
there is a relapse after 12 months from the therapy. More-
over, EOC patients relapsing between 6 and 12  months 
show an intermediate sensitivity to platinum; for this rea-
son, they are called platinum-partially sensitive. Longer 
the interval from the end of platinum-based chemother-
apy, better is the outcome using platinum again [6, 7].
Based on the classical abdominal spread, besides clas-
sical chemotherapy which has been in use over the years, 
an intraperitoneal chemotherapy has been developed [8].
The response rate (RR) to chemotherapy is high, with 
higher rate of relapse.
Therefore, recurrent EOC constitutes a poor prog-
nosis disease, forcing patients to receive multiple lines 
of chemotherapy, with unsatisfactory results due to the 
occurrence of drug-resistant cancer clones. For these rea-
sons, and in order to identify more appropriate therapeu-
tic options, a considerable scientific interest towards the 
identification of alternative molecular pathways, involved 
in ovarian carcinogenesis and new drugs related, has 
developed [9].
Among these new compounds, anti-angiogenetic target 
therapies have shown activity in association with stand-
ard chemotherapy in several trials; particularly bevaci-
zumab (BV) in four phase III trial showed an increase of 
progression free survival (PFS) and overall survival (OS) 
[10–12].
Although standard treatments can effectively reduce 
tumor mass, a lot of patients with residual ovarian can-
cer stem cells (CSCs), could acquire chemo-resistance 
[13–15].
In this context, the CSC theory supports that even if a 
small number of CSCs remains in situ after therapy, dis-
ease recurrence can occur [16]. Several CSC’ pathways 
could be involved in these mechanisms including activa-
tion of anti-apoptotic factors, inactivation of pro-apop-
totic effectors, and/or reinforcement of survival signals 
[17–19].
With the advent of next-generation sequencing in 
recent years, EOC has been found to consist of a complex 
set of diseases. Diverse genetic or epigenetic alterations 
that are of fundamental importance in tumorigenesis and 
progression have been identified in heterogeneous sub-
sets of patients [20].
For example, BRCA1/2 germ-line mutation is essen-
tially associated with HGSOC [21]. The prevalence of 
germline breast related cancer antigens (BRCA) muta-
tions (gBRCAm) in EOC has historically been estimated 
to be around 10–15  % [22]. Recent reports suggest that 
this may be a gross underestimate, especially in women 
with HGSOC [23].
The emergence of the DNA repair pathway as a rational 
target in various cancers led to the development of the 
PARP inhibitors (PARPi) [24].
PARPi exploit the mechanism of ‘synthetic lethality’, 
that is loss of function in two genes causes cell death as 
opposed to a non-lethal effect of functional loss of one of 
the genes, to target tumours with defective DNA repair 
mechanisms, such as aberrant homologous recombina-
tion (HR) repair due to loss of BRCA1 and 2 gene func-
tion through the presence of mutations [25].
Such data support the use of BRCA mutation testing 
in all patients with HGSOC, regardless of family history. 
This expansion in BRCA testing will require changes to 
the traditional genetic service pathways in which patients 
are screened and referred based on family history, mov-
ing to a more streamlined oncology-based genetic testing 
service.
Determining the molecular events that control this 
tumour trait might advance the understanding of tumori-
genesis and facilitate individualized treatment strategies 
for this lethal disease.
BRCA and PARP role in DNA stability system
DNA continually sustains damaging alterations under a 
constant barrage of environmental insults, toxic products 
of metabolism, and erroneous DNA replication. These 
alterations can be divided into: base modifications; sin-
gle strand breaks (SSB); double strand breaks (DSB); and 
intrastrand or interstrand cross-links [26].
Several DNA repair mechanisms have evolved to repair 
these lesions and maintain genomic integrity. Given the 
large array of potential lesions and the importance of 
high-fidelity repair, DNA repair mechanisms are gener-
ally complex, highly redundant, and to a large extent con-
served across phylogenetic classes [27] (Fig. 1).
SSB repair mechanisms include base excision repair 
(BER), nucleotide excision repair (NER) and mismatch 
repair (MMR) pathways [28].
Amongst the various DNA insults, single strand altera-
tions occur most often at a rate of approximately 104 per 
day and are repaired through a combination of BER, NER 
and MMR mechanisms using the intact DNA strand as a 
template. The predominant pathway of SSB repair is the 
BER utilizing PARP [29].
PARP is a nuclear protein that senses and binds to 
DNA SSB and subsequently activates the BER pathway 
by recruiting additional repair factors. Of the 17 known 
members of the PARP super-family in humans, PARP-1 
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accounts for more than 90 % cellular DNA repair activity 
and remains the most studied [30, 31].
PARP-1 is recruited and activated by SSBs as a 
homodimer in a fast reaction and upon binding to a 
damaged strand; PARP-1 undergoes a conformational 
change inducing the C-terminal catalytic domain to 
transfer ADP-ribose moieties from cellular nicotina-
mide-adenine-dinucleotide (NAD+) to protein accep-
tors, including the central auto-modification domain of 
PARP1 itself. The major mechanism that limits the PAR-
ylation of protein acceptors is PAR hydrolysis by Poly-
(ADP-ribose) glucohydrolase (PARG). The amount of 
PAR present in the cell depends on the balance between 
PARP1, and PARG. PARP-1 function is restored by 
the degradation of PAR. In case of small to moderate 
damage, PARP-1 allows for the restoration of genomic 
integrity and the return to normal cellular function. 
However, emerging evidence has implicated PARP-1 
over activation in unregulated PAR synthesis, depleting 
NAD, and consequently ATP, eventually leading to 
widespread cell death. In this recently characterized 
model, PARP-1 over activation results in the synthesis 
of numerous long branched PAR polymers which trig-
gers the translocation of apoptosis-inducing factor from 
mitochondria to the nucleus resulting in caspase-inde-
pendent cell death [32].
The lengthening PAR chain builds up a large negatively 
charged structure at the SSB which recruits other DNA 
repairing enzymes. These include DNA ligase III (LigIII), 
DNA polymerase beta (polβ), and scaffolding proteins 
such as X-ray cross complementing gene 1 (XRCC1), that 
collectively form the BER multi-protein complex. Among 
the proteins it recruits, XRCC1 is crucial for DNA repair, 
initially assembling and activating the BER machinery 
through the modification of several proteins such as 
histones and topoisomerases but subsequently “switch-
ing off” the BER machinery by decreasing the affinity of 
both histones and PARP-1 to DNA. As it dissociates from 
Fig. 1 A panoply of DNA repair mechanisms maintains genomic stability. DNA is continually exposed to a series of insults that cause a range of 
lesions, from single-strand breaks (SSBs) to base alkylation events. The choice of repair mechanism is largely defined by the type of lesion, but 
factors such as the stage of the cell cycle also have a role. Key proteins involved in each DDR mechanism, the tumour types usually characterized 
by DDR defects and the drugs that target these defects are shown. BER base excision repair, NER nucleotide excision repair, NHEJ non-homologous 
end-joining. Figure modified, with permission, from Lord et al. [24]
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DNA, PARP-1 becomes inactive and no further synthesis 
of the PAR polymer occurs [33].
Regarding DSB repair mechanisms, they consist of HR 
and non-homologous end-joining (NHEJ) pathways. HR 
consists of gene conversion and single-strand anneal-
ing pathways. This pathway is mostly active in the S and 
G2 phases of the cell cycle. Crucial proteins involved in 
mediating homologous recombination include those 
encoded by the BRCA1, BRCA2, RAD51 and PALB2 
genes. The BRCA1 and BRCA2 proteins are important in 
maintaining genomic stability by promoting efficient and 
precise repair of DSB [34, 35] (Fig. 1).
PARP inhibitors in BRCA mutated EOC 
and synthetic lethality concept
PARPi mediate their anti-cancer effects as catalytic 
inhibitors blocking repair of DNA SSBs by the BER/
SSBR pathway (Fig.  1). The initial clinical development 
of PARPi focused on their role as chemo-sensitizers, and 
their single-agent activity was unknown. Ten years ago 
two articles published in Nature reported that BRCA1/2 
heterozygote or wild-type cell lines were 100- to 1000-
fold less sensitive to PARP inhibitors than cells deficient 
in BRCA1 and 2 [36, 37]. The conclusion of both studies 
was that the BRCA-deficient cells were selectively sen-
sitive to PARP inhibition by a mechanism of ‘synthetic 
lethality: cancer cells are selectively sensitive to the inac-
tivation of two genes or pathways when inactivation of 
either gene or pathway alone is non-lethal. PARP inhibi-
tors inhibit the repair of DNA SSBs by the BER/SSBR 
pathway leading to cell death [38].
If the cell cannot initiate HR, as is the case with 
BRCA1/2-mutant tumors, it resorts to more error-prone 
pathways, such as non-homologous end joining or single-
strand annealing, which can cause gross chromosomal 
mutations, growth inhibition, and eventual cell death 
[39].
Then, patients with EOC with germline mutations in 
either BRCA1 or BRCA2 genes exhibit impaired ability to 
repair DNA DSB via HR, and show a heightened sensitiv-
ity to inhibitors of the BER pathway [40].
The identification of BRCA mutations represented a 
significant breakthrough in the management of breast 
and OC families, enabling the introduction of risk assess-
ment and genetic counseling. Over 2000 distinct muta-
tions and sequence variations have been identified with 
BRCA1 mutations more common, occurring approxi-
mately twice as frequently as BRCA2 [41].
Data from 26 observational clinical studies of 3879 
women with OC reported that those with BRCA-mutated 
cancers have a better outcome following cytoreductive 
surgery and platinum based chemotherapy than their 
non-BRCAm counterparts [42]. The Cancer Genome 
Atlas Research Network carried out an analysis in which 
the sequencing of 316 stage-II–IV HGSOC was com-
pared the matched normal DNA. BRCA1 and BRCA2 
germline mutations were identified in 9 and 8  % of the 
cases, respectively. An additional 3  % showed somatic 
mutations of the BRCA genes; therefore, a total of 20 % of 
HGSOC exhibited a BRCA mutation [43].
Many sporadic EOC share pathological and clinical 
traits of BRCA mutation-associated cases, in the absence 
of a gBRCAm. This condition, in which a HR DNA repair 
defect is present, but no germline BRCA1 or BRCA2 
mutation is detected, is termed as “BRCAness” [40, 44].
Recent reports proposed alternative models of syn-
thetic lethality. For example, PARP inhibitors themselves 
can be directly toxic to cells by trapping PARP-1 and 2 
and forming PARP-DNA complexes; this could lead 
to replication forks obstruction, which require BRCA 
dependent HRR to be resolved [45].
Interestingly, depleting PARP through siRNA has been 
shown to be less cytotoxic than depleting PARP with 
PARPi [46] (Fig. 1).
Clinical trials of single parp inhibitor
Olaparib
Olaparib is the first PARPi to be introduced in clinical 
practice in relapsed EOC. In the expansion phase of the 
phase I trial, olaparib 200  mg twice day showed a 28  % 
radiologic response in relapsed BRCA1/2 mutated EOC, 
with a response duration of 7 months [47] (Table 1).
Monotherapy with olaparib was then investigated in 
a non-randomized trial, in which it was administered in 
two schedules: 100 mg twice daily and 400 mg twice daily. 
Enrolled patients were heavily pretreated EOC patients 
with BRCA1 and BRCA2 germline mutations. 100  mg 
twice daily showed a 13  % ORR, while olaparib 400  mg 
twice daily achieved a 33 % ORR. These results were not 
linked to BRCA1 or BRCA2 mutations. Similar results 
were seen in platinum-sensitive and in platinum-resist-
ant EOC. The most frequent adverse events (AEs) were 
fatigue and nausea. Two grade 5 AEs occurred: a cardiac 
failure and an intestinal perforation. A patient developed 
a myeloid leukemia 9 months after the discontinuation of 
olaparib [48] (Table 2).
In a phase II trial [49] olaparib was tested at two dose-
levels, 200 and 400 mg twice daily, versus pegylated lipo-
somal doxorubicin (PLD), given 50 mg/m2 every 28 days, 
in a population of BRCA1/2 mutated EOC patients, with 
a platinum-free interval of less than 12 months. Primary 
endpoint was investigator assessed PFS, secondary end-
points were ORR, duration of treatment response (DOR), 
tumor size, OS, safety and tolerability, health-related 
quality of life (QoL). Ninety-seven patients were enrolled: 
32 to olaparib 200  mg twice daily arm; 32 to olaparib 
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400 mg twice daily arm and 33 in the PLD arm. No signif-
icant differences in PFS were observed between groups. 
Also ORRs and DOR were not statistically different. A 
significant difference was achieved by olaparib 400 mg vs 
PLD in Ca125 response (Table 1). Most common AEs in 
olaparib group were fatigue, anemia, gastrointestinal dis-
orders and rash, mostly < grade 2. In the PLD arm grade 
3 AEs were more frequent, in particular stomatitis, pal-
mar-plantar erythrodysesthesia and rash. Grade 3 anemia 
was more frequent in the olaparib 400  mg arm than in 
the PLD arm. There were no significant differences in the 
health-related QoL between arms (Table 2).
Monotherapy with olaparib 400  mg twice daily 
has been investigated in another open-label non-
randomized phase II trial [50] in heavily pre-treated 
patients, carrying BRCA1 or BRCA2 mutations, with 
EOC or breast cancer. Patients were divided in 4 cohorts 
according to primary tumor and BRCA mutational sta-
tus. Overall 86 patients were evaluable for objective 
response: 63 in OC cohort, 23 in breast cancer cohort. 
ORR was greater for BRCAm then for non-mutated. 
The DCR in the OC population was 66 %. Five patients 
of 64 in OC cohort discontinued treatment due to AEs. 
In post hoc ORR in patients with platinum-sensitive OC 
were 50 % in the BRCA1 or BRCA2 negative cohort and 
60 % in the BRCA1 or BRCA2 positive mutation cohort. 
Platinum-resistant OC responses were seen in 33  % 
of those in the mutation-positive cohort, but in only 
4  % of those in the BRCA1 or BRCA2 negative cohort 
(Table 1).
Table 2 PARP inhibitors in ovarian cancer–G3/G4 Adverse Events
OLA Olaparib, VEL veliparib, CED cediranib, RUC rucaparib, NIR niraparib, PLA placebo, unk unknown, mt mutated, wt wild type, Pts patients, NR not reported, P 
Paclitaxel, CBDC Carboplatin, Res platinum resistant, Ref platinum refractory, CT chemotherapy
OLA (%) OLA+CED (%) OLA+CT (%) VEL (%) VEL+CHT (%) NIR (%) RUC (%) INI (%)
Nausea 0–8 5 1 1 0 0 3 0
Vomiting 0–4 0 0 0 0 0.5 0 0
Diarrhoea 0–5 23 0 0 0 0 0 8.3
Dehydration 0 0 0 0 0.4 0 0 0
Hyponatremia 0 0 0 0 0.7 0 0 8.3
Abdominal pain 0–8 0 0 0 0 0 1 0
Headache 0 5 1 0 0 0 0 0
Constipation 0–2 0 0 0 0 0 0 0
Decreased appetite 0–2 0 1 0 0 0.5 0 0
Upper abdominal pain 0 0 0 0 0 0 1 0
Arthralgia 0–1 0 0 0 0 0 0 0
Back pain 0–2 0 0 0 0 0 0 0
Asthenia/fatigue 3–11 27 7 0 0 1.5 6 0
Abdominal distension 0–3 0 0 0 0 0 0 0
Leucopenia 0–2 0 5 0.5 0.7 0 0 0
Neutropenia 0–9 0 43 0.5 0.7 1.5 0 0
Lymphopenia 0–4 0 0 0 4.8 0.5 0 8.3
Thrombocytopenia 0 0 6 0.5 0.4 3.5 0 0
Anemia 0–20 0 9 0 0.7 3 0 0
Hypertension 0 41 0 0 0 0 0 8.3
Peripheral sensory neuropathy 2 0 0 0 0 0 0 0
Drug hypersensitivity 0 0 5 0 0 0 0 0
Dyspnea 4 0 0 0 0 0 0 0
Increased AST 0 0 0 0 0 0 0 8.3
Increased ALT 0 0 0 0 0 0 0 16.7
Increased activated partial thromboplastin time 0 0 0 0 0 0 0 8.3
Hyperbilirubinemia 0 0 0 0 0 0 0 8.3
Increased alkaline phosphatase 0 0 0 0 0 0 0 16.7
Increased international normalized ratio 0 0 0 0 0 0 0 16.7
Malignant pleural effusion 0 0 0 0 0 0 0 8.3
Gastro-oesophageal reflux disease 4 0 0 0 0 0 0 0
Death 0 0 0 0 0 0 0 8.3
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Olaparib has also been investigated in association with 
cediranib [51], a VEGR 1-2-3 oral tyrosine-kinase inhibi-
tor, in a phase II trial, showing 9.0 months PFS for olapa-
rib arm and 17.7 months for cediranib and olaparib arm. 
The association showed to be more effective in BRCA 
wild type patients, while in BRCAm patients the differ-
ences were smaller (Table 1). Adverse events were more 
common in the association arm (Table 2).
Olaparib has been evaluated, vs placebo, as mainte-
nance therapy in patients with recurrent platinum-sensi-
tive EOC, fallopian tube cancer and primary peritoneal 
cancer. The first results showed a PFS increase for olapa-
rib against placebo, with no statistical difference for OS 
[52]. Results were even better in BRCAm population. 
Data for OS were not mature, showing no statistically 
significant differences between groups (Table 1). QoL did 
not differs between groups [53].
Preclinical data showed that olaparib could potenti-
ate the effect of DNA-damaging chemotherapy. This 
hypothesis has been investigated by Oza et al. [54], that 
evaluated carboplatin and paclitaxel alone or in combi-
nation with olaparib 200 mg twice daily in patients with 
EOC, fallopian tube cancer or primary peritoneal cancer 
progression-free for at least 6 months. After 4–6 cycles 
of combination treatment, patients in the experimen-
tal arm continued olaparib monotherapy 400  mg twice 
daily until disease progression or toxicity. 162 patients 
were randomly assigned to the two groups; BRCAm 
status was known for 107 patients, 41 were mutated. At 
the primary analysis olaparib arm showed a significant 
PFS increase. This increase was even bigger in BRCAm 
patients. OS did not significantly differed between 
groups, like the percentage change in tumor size, the 
proportion of patients with objective response, the 
Ca125 response and the ovarian cancer response. The 
exploratory analyses of time to first subsequent therapy 
or death and time to second subsequent therapy or death 
showed a significant benefit in time to first subsequent 
therapy or death in favor of the olaparib plus chemother-
apy group, but no significant difference in time to sec-
ond subsequent therapy or death between the groups. In 
BRCAm patients the use of olaparib led to a significant 
increase in these criteria (Table 1). Adverse events were 
more frequent in the olaparib arm, with an increased 
rate of alopecia, nausea, neutropenia, diarrhoea, head-
ache, periferal neuropathy and dyspepsia, with a higher 
rate of grade 3 AEs (Table 2).
In another single arm phase II trial [55] olaparib has 
been evaluated in several kind of cancer with BRCA1/2 
germline mutations. The 298 patients enrolled had EOC, 
breast cancer, pancreatic cancer and prostate cancer, all 
progressed after standard therapies. Patients were treated 
with olaparib 400 mg twice daily until disease progression 
or toxicity. Of the 298 patients enrolled, 178 had EOC, 11 
had primary peritoneal cancer and 4 had fallopian tube 
cancer. For all patients ORR was 26.2: 31.1  % for EOC; 
12.9  % for breast cancer; 21.7  % for pancreatic cancer; 
50  % for prostate cancer. Median duration of response 
was 208 days, 225 for EOC; stable disease at 8 weeks was 
achieved in 41.6 % patients (40.4 % for EOC). Response 
were similar between BRCA1 and BRCA2 mutation car-
riers. Median PFS was 7, 3.7, 4.6 and 7.2 months for ovar-
ian, breast, pancreatic and prostate cancer. Median OS 
was respectively 16.6, 11, 9.8 and 18.4 months. The most 
common Grade 3 AEs were anemia and fatigue.
About EOC population of the same trial, in particular 
patients treated for more than 3 lines of chemotherapy, 
further data were published by Domcheck et  al. [56]. 
In addition to the previously published data, that were 
encouraging, we can see how the platinum sensitivity 
can influence the action of olaparib, indeed Platinum-
sensitive population showed better outcome in all the 
endpoints. Serious AEs were reported in 30  % patients, 
frequently anemia, abdominal pain, intestinal obstruc-
tion and pleural effusion (Table 2).
A pooled analysis [57] of all EOC patients with 
BRCA1/2 germline mutations, treated with olaparib 
monotherapy 400 mg twice daily, showed that the treat-
ment is effective and associated with durable responses. 
The ORR declined with the increase of the previous lines 
of treatment (Table 1). The 50 % of patients experienced 
Grade 3 AEs, with 38  % interruptions due to adverse 
events, the most common cause being vomiting and ane-
mia (Table 2).
Veliparib
Coleman et  al. [58] evaluated the use of single agent 
veliparib in relapsed EOC in a phase II trial. Fifty-two 
patients with relapsed BRCA1-2 mutated EOC, were 
enrolled to receive Veliparib 400  mg BID until progres-
sion or toxicity. The most common hematological tox-
icities were anemia and leukopenia, mostly grades 1–2 
(Table 2).
There were 2 complete responses (CR) and 11 partial 
responses (PR), and 24 SD (Table  1). 27 patients were 
progression-free at 6 months. Veliparib showed objective 
response in platinum-sensitive and in platinum-resistant 
populations.
Veliparib was also evaluated in association with chem-
otherapy. After a phase I trial [59], in which veliparib was 
administered in association with oral cyclophosphamide 
with encouraging results, Kummar et al. [60] enrolled 75 
patients with BRCAm ovarian, primary peritoneal and 
fallopian tube cancer, progressed after at least 1 line of 
standard therapy, to evaluate objective response of veli-
parib plus cyclophosphamide versus cyclophosphamide 
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alone. The addition of veliparib did not improve ORR on 
cyclophosphamide alone, for this reason patient accrual 
was early closed.
The use of veliparib was also evaluated in association 
with doublets. In a phase I trial [61] veliparib was admin-
istered in association with carboplatin, PLD and bevaci-
zumab (BV). Objectives of the study were to determine 
maximum tolerated dose (MTD) and dose limiting toxic-
ity (DLT) of this association. Patients with EOC, fallopian 
tube cancer and primary peritoneal cancer, progressed 
after 1 line of chemotherapy, with at least 6  months of 
platinum-free interval were eligible. The addition of 
veliparib to a platinum-based chemotherapy showed an 
important effect on bone marrow, with a great increase 
in thrombocytopenia and neutropenia, while BV did not 
add significant toxicity to this combination.
Rucaparib
Rucaparib is a PARPi active against both PARP1 and 
PARP2 [62]. Furthermore it showed some activity against 
tankyrase TANK1, PARP5A and PARP5B [63]. In preclin-
ical models rucaparib showed activity not only in BRCA-
mutation carriers, but also in deficient-HR, like XRCC3 
and epigenetically BRCA silenced [64].
In the trial by Drew et al. [65] i.v. rucaparib was admin-
istered daily for 5  days every 21  days, in patients with 
breast and EOC. The trial was divided in two stages: stage 
1 was a short dose-escalation phase; in stage 2 efficacy 
and safety of rucaparib were evaluated at the dose of the 
stage 1. After the introduction of oral rucaparib, study 
design was amended and trial reopened to investigate 
oral rucaparib. The oral rucaparib starting dose was set at 
92 mg once daily. Primary endpoints were ORR and tox-
icity of i.v and oral rucaparib. Secondary endpoints were 
determining a tolerable and effective dosing regimen for 
oral rucaparib, time to progression, OS. 78 patients were 
enrolled, 48 patients were BRCA1 m, 26 were BRCA2 m. 
Of the 78 patients enrolled, 51 had EOC and the median 
number of prior chemotherapy was 2. Rucaparib showed 
interesting results, in particular achieving a lot of SD. In 
EOC patients the greater results were seen in patients 
with the longest platinum free interval (Table 1).
Oral rucaparib was well tolerated up to a dose of 
480 mg per day. No DLTs were seen in the i.v. phase of 
the study. The most common AEs were fatigue and nau-
sea (Table 2).
Saphira-Frommer et  al. [66] evaluated rucaparib in 
relapsed EOC patients. Patients received oral ruca-
parib 600 mg BID in 21 day cycles until disease progres-
sion. The primary endpoint was ORR by RECIST 1.1., 
RECIST/CA-125 ORR was 81  %. The most common 
treatment-related AEs (generally grade 1/2) were nau-
sea, anemia, ALT/AST elevations, fatigue, and asthenia 
(Table 2).
Niraparib
Niraparib, a PARP1 and PARP2 inhibitor, has been stud-
ied in a phase I dose-escalation trial [67]. In the part A of 
the trial, eligible patients had several kinds of malignan-
cies, not suitable for standard treatments. In the part B 
of the trial only patients with sporadic platinum-resist-
ant EOC and castration-resistant prostate cancer were 
enrolled. At the end of the part A, 400 mg was found to 
be the MTD, however 300 mg was defined to be the rec-
ommended dose in phase II trials.
Overall, 77 patients showed a response according to 
RECIST criteria. Among the patients in the part A, 29 
showed mutations in BRCA 1 or BRCA2. 22 patients had 
EOC. Twenty of these 22 patients had measurable dis-
ease, showing PR in 8 patients (40 %) with doses between 
80 and 400 mg. Three of 9 patients with platinum-resist-
ant EOC showed RECIST and Ca125 responses; another 
patient had SD for 120 days.
Iniparib
Iniparib was initially developed as a prodrug of the most 
reactive INOBA, a molecule with a powerful PARP-inhi-
bition. Preclinical studies showed an anti-proliferative 
effect in triple-negative breast cancer cell lines, causing 
an arrest in G2/M phase; [68] however in  vitro studies 
showed that iniparib had not a classic PARP inhibition. 
Also other evidences underlined this particular action of 
iniparib in different cell lines, in particular HR deficient 
cell lines exposed to veliparib, olaparib and iniparib had 
a sensitivity to the first two drugs, while iniparib had not 
an action in HR deficient cells [69]. While in triple-nega-
tive breast cancer iniparib showed interesting results in a 
phase II trial [70], not confirmed in the phase III [71], in 
EOC addition of iniparib did not reached positive results 
[72–74].
Talazoparib
Talazoparib is an oral PARP-inhibitor that exhibits cyto-
toxic activity at a lower concentration than other PARP-
inhibitors. In a phase I trial [75] recommended phase 
II dose was established at 1  mg/die. The most frequent 
dose-limiting toxicity was thrombocytopenia. Talazo-
parib showed interesting results in heavily pre-treated 
small-cell lung cancer and in BRCAm breast and EOC. 
Phase II trials are ongoing [76, 77].
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Resistance to parp‑inhibition
Tumor heterogeneity could be a possible cause for resist-
ance to PARP-inhibition. This phenomenon is consistent 
with classical Darwinian evolutionary theory [78].
Resistance to PARP-inhibition could depend on differ-
ent mutations in BRCA genes: analysis of BRCA genes 
showed that the C- and the N-terminal domains are fun-
damental for the functioning of PARP-inhibition [79]. For 
example, the level of genomic instability of mouse tumors 
carrying the BRCA1-C61G RING inactivating mutation 
is identical to that of BRCA1-null tumors, tumor cells 
with BRCA1-C61G RING inactivating mutation develop 
a resistance to PARP-inhibition [80].
Rottenberg et al. [81] identified a possible mechanism 
of resistance in BRCA-deficient murine model treated 
with olaparib, caused by an up-regulation of Abcb1a/b 
genes encoding P-glycoprotein efflux pumps. The pres-
ence of this pump causes efflux of the drug outside the 
cell, limiting its activities. The coadministration of p-gly-
coprotein inhibitor tariquidar reversed this resistance.
Edwards et al. [82] showed in CAPAN1 pancreatic cell 
lines that resistance to PARP-inhibition can be acquired 
by deletion of a mutation in BRCA2. This second muta-
tion could by-pass or correct the original mutation, 
restoring the physiological activity of HR.
Another possible mechanism of resistance to PARP-
inhibition is loss of 53BP1. In murine model, somatic 
loss of 53BP1 causes the restoration of HR. In addition it 
seems that the same loss could be responsible for chemo-
therapy resistance in the same population [83].
Conclusions
PARP inhibition leads to the persistence of spontane-
ously occurring SSBs and subsequent formation of DSBs, 
as the SSBs stall and collapse replication forks. These 
DSBs cannot be repaired by the defective HR pathway 
in BRCA-mutated cells, resulting in cell death. PARPi 
induce synthetic lethality in BRCA-deficient tissues. 
BRCA1/2-deficient cancers are now recognized as the 
target of a class of drugs known as PARPi. Deficiency 
of either PARP or BRCA alone has no impact, but defi-
ciency in both leads to a lethal effect.
These data suggest that there is likely to be a role for 
PARPi in the treatment of EOC. PFS appears to be 
improved in women with recurrent platinum-sensitive 
disease, with manageable side effects. However, ben-
eficial effects in terms of OS have not been adequately 
demonstrated and more data are required to determine 
whether longer PFS translates into an improved OS. 
More data are expected from ongoing phase III clinical 
trials. The European Medicines Agency (EMA) approved 
olaparib for monotherapy for the maintenance treat-
ment of adult patients with platinum sensitive relapsed 
BRCAm (germline and/or somatic) HGSOC, fallopian 
tube, or primary peritoneal cancer who are in response to 
platinum-based chemotherapy in 2014.
In the absence of more refined understanding of 
PARPi action, BRCA1/2 mutation status has been the 
most extensively studied predictor of PARPi sensitivity 
to date. When PARPi are administered as single agents 
in the relapsed setting, BRCA1/2-mutated OC has a 
30–45 % ORR, with better responses in platinum-sensi-
tive EOC.
In the meantime, two lines of clinical development 
were actively pursued. First of all, the concept that PARP 
inhibition in EOC might have utility extending beyond 
those cases associated with BRCAm. The key property 
predicting efficacy is HRD, and in 2011, Levine’s work 
within the Cancer Genomic Atlas framework indicated 
that up to 50 % of cases of HGSOC might be candidates 
for PARPi, based on a range of genetic defects in addition 
to BRCA 1 or 2 germline and somatic mutations [43].
The clinical relevance of the observations was assessed 
in a clinical trial published in 2011, which demonstrated 
efficacy of olaparib in a series of patients with sporadic, 
BRCA wild-type EOC, albeit at a slightly lower level 
(24  %) and confined mainly to patients with platinum-
sensitive disease [48, 49].
The second line of investigation, which led directly 
to the approval of olaparib by regulatory authorities in 
Europe, examined the use of the drug as a form of main-
tenance therapy. The key randomized trial involved 
patients with platinum-sensitive relapsed disease who 
received single-agent olaparib or placebo following plat-
inum-based treatment. The trial had not selected for 
patients with BRCAm, and mutation status was initially 
unknown in the majority of cases (64 %) [52].
However, retrospective analysis indicated that 136 
patients (51  %) were positive for BRCA 1 or 2, and the 
treatment benefit in this subgroup was even more 
marked (HR = 0.17).
Other notable features in this retrospective analysis 
included the positive benefit in patients with BRCA wild-
type disease and in those with sBRCAm and both these 
observations will be taken forward in subsequent trials 
involving olaparib as well as two other PARPi (niraparib 
and rucaparib).
Accumulating evidence suggests that PARPi may have 
a wider application in the treatment of sporadic EOC. Up 
to 50  % of HGSOC patients may exhibit HRD through 
mechanisms including gBRCAm, sBRCAm, and BRCA 
promoter methylation [84].
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It is now well established that gBRCAm EOC have a 
relatively distinct clinical behavior characterised by an 
earlier age at diagnosis, improved survival, visceral distri-
bution of disease, higher response rates to platinum and 
certain non-platinum chemotherapy agents and sensitiv-
ity to PARPi [85–87].
However, it became increasingly apparent that a pro-
portion of sporadic EOC also share pathological and 
clinical traits of BRCA mutation-associated cases, but 
in the absence of a gBRCAm. This concept, termed as 
‘BRCAness’ over a decade ago, now describes the situa-
tion whereby a HR DNA repair defect is present, but no 
germline BRCA1 or BRCA2 mutation is detected [44].
This is becoming increasingly relevant clinically as the 
activity of PARPi has now been demonstrated in trials to 
extend beyond gBRCAm EOC [87].
The first demonstration of clinically meaningful activ-
ity of a PARPi in EOC patients without a gBRCAm was 
provided by Gelmon et al. [50] in a phase II study which 
included patients with HGS/undifferentiated OC with 
unknown BRCA status or BRCA-negative treated with 
olaparib.
Evidence for attributing the ‘BRCAness’ phenotype to 
HRD due to the mechanisms other than germline muta-
tions in BRCA1 or BRCA2 comes from several studies 
[88].
HRD leads to massive genomic instability resulting in 
tumour formation. In addition, HRD cancers are poten-
tially sensitive to drugs that induce lesions that are nor-
mally repaired by the HR pathway. Furthermore, the 
synthetic lethal interaction described with PARPi may 
be exploited beyond gBRCAm EOC in the context of 
HRD. Several genetic lesions causing HRD include ger-
mline and somatic BRCAm as well as mutations of genes 
such as ATM, CHEK2, BARD1, BRIP1, MRE11, RAD50, 
NBS1, RAD51C, RAD51D and PALB2. It is clear that if 
the indication for PARPi is to expand into a BRCA-wild 
type population, robust tests with a high probability of 
determining HRD status are needed [89–92].
In contrast, not all patients with deleterious BRCA1 
or BRCA2 mutations at diagnosis respond to PARPi. In 
cell lines, secondary somatic mutations in BRCA1- or 
BRCA2-mutant cancer cells can restore protein expres-
sion, reconstitute HR, and confer resistance to PARPi and 
platinum.
Secondary mutations that restore BRCA1 and BRCA2 
also predict platinum and PARPi resistance in the clini-
cal setting. It seems that approximately 45 % of recurrent 
platinum-resistant BRCA1/2-mutated EOCs have sec-
ondary somatic mutations.
Interestingly, clinical cancer specimens most com-
monly sustain secondary somatic mutations that revert 
the mutant allele to wild-type sequence, making second-
ary mutations highly predictive of response but techni-
cally difficult to identify.
In addition to reversion mutations, HR can be restored 
in other ways. Some mutant BRCA1 alleles encode pro-
teins that are potentially functional but degraded rapidly. 
Stabilization of these mutant proteins can restore HR and 
confer PARPi resistance without any secondary BRCA1 
mutation.
Likewise, decreased expression of 53BP1, which ordi-
narily channels DSB repair to NHEJ, restores HR and 
confers PARPi resistance in BRCA1-mutant cells despite 
the continued absence of BRCA1 protein.
The extent to which these mechanisms contribute 
to PARPi resistance in clinical EOC remains to be fully 
defined. Despite the current focus on BRCA1/2 muta-
tion carriers with EOC, responses are not limited to this 
group. EOCs with somatic BRCA1/2 mutations seem to 
be as likely to benefit from PARPi maintenance therapy 
as those with inherited mutations, although the num-
ber of treated patients with somatic mutations is small. 
Moreover, germline or somatic mutations in other genes 
critical to HR correlate with platinum sensitivity in EOC 
and might also predict PARPi response.
In addition to mutations, other processes, includ-
ing epigenetic alterations and changes in expression of 
microRNAs or transcription factors, could in principle 
impair HR and confer PARPi sensitivity. BRCA1promoter 
hypermethylation, which downregulates BRCA1 expres-
sion, occurs in 10–15 % of OCs and has been proposed as 
a mechanism of HRD.
However, data from The Cancer Genome Atlas and 
others fail to correlate BRCA1 hypermethylation with 
increased platinum sensitivity or improved survival, 
suggesting that epigenetic BRCA1 downregulation may 
have a less profound impact on HR and PARPi sensitivity 
than inactivating BRCA1 mutations. In short, improved 
understanding of PARP biology and HRD is providing 
important new clues for predicting PARPi responders vs 
non responders.
Questions remain about how best to use PARPi, 
whether to use in combination with chemotherapy or as 
maintenance alone. Possible combination treatment with 
PARPi include anti-angiogenic agents or in combination 
with cyclophosphamide or weekly paclitaxel. Pre-clinical 
data suggest that inhibiting vascular endothelial growth 
factor receptor (VEGFR) may lead to down-regulation 
of DNA-repair activity by DNA-repair proteins, ERCC1 
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and XRCC1 [93]. The mechanism of this therapeutic 
approach is to induce HRD in otherwise HRR-compe-
tent cancers by altering the tumour microenvironment 
through hypoxia, or to combine PARPi with agents 
that can downregulate HRR, such as vascular endothe-
lial growth factor (VEGF) inhibitors. This may lead to 
increased DNA damage and, thereby, increase suscep-
tibility to the effects of PARPi. This concept, known as 
‘contextual’ synthetic lethality, could further broaden 
the application of this class of drugs and is the rationale 
behind many ongoing clinical trials.
Clinical studies of PARPi in combination with chemo-
therapy agents are ongoing (Table  3). Future studies 
should include OS and QoL as important outcomes. In 
women with platinum-resistant EOC objective responses 
to both PARPi and PLD were demonstrated at higher lev-
els than previous studies of women with platinum-resist-
ant EOC in non-selected populations [49].
Beyond olaparib, other PARPi that have been tested 
or are currently being tested in clinical trials for EOC 
include veliparib, niraparib, rucaparib, talazoparib and 
iniparib.
Radiotherapy, inducing DNA damage by multiple 
mechanisms including base damage and SSB and DSB 
DNA, could be a fascinating partner for PARPi therapy 
[94–96]. A work by Anthony Chalmers’ group has shown 
that this radio-potentiation is enhanced in rapidly pro-
liferating cells and cells defective in DNA DSB repair 
compared with normal tissue [97]. These data support a 
role for combining radiotherapy and PARPi in patients 
with cancer, and clinical trials are finally underway with 
results eagerly awaited.
Based on a body of evidence and the clinical success of 
immunotherapy in many malignancies, it is confirmed 
that blocking the programmed death 1 (PD-1) and its 
ligands in EOC is feasible and valid both in animal mod-
els and patients. Immunotherapy may play a significant 
role in the future clinical management and improve the 
prognosis of EOC. The phase 2 trial that first to explore 
the effects of nivolumab (anti-PD-1 mAb) against plati-
num-resistant EOC has published the safety and antitu-
mor activity results [98].
PD-1 immune checkpoint blockade provides significant 
clinical benefits for melanoma patients; moreover, high 
mutational loads are associated with improved survival 
in melanoma patients but are not predictive of response 
to anti-PD-1 therapy, suggesting that other genomic and 
non-genomic features also contribute to response pat-
terns on PD-1 checkpoint blockade therapy. Hugo et al. 
analyzed the somatic mutanomes and transcriptomes of 
pretreatment melanoma biopsies to identify factors that 
may influence innate sensitivity or resistance to anti-
PD-1 therapy; and they find that overall high mutational 
loads associate with improved survival, and tumors from 
responding patients are enriched for mutations in the 
DNA repair gene BRCA2. Thus, BRCA2 loss-of-function 
mutations, which are expected to produce defects in HR 
and DSB DNA break repair, may produce specific muta-
tional signatures or unknown effects (e.g., induction of 
cell death) that contribute to anti-PD-1 responsiveness 
[99, 100].
Moreover, considering PARPi mechanism of action, 
their use could further increase the mutational loads in 
BRCAm EOC patients; therefore it would be very inter-
esting to evaluate the effectiveness of the combination 
of PARPi and anti-PD1 or anti-CTLA4 in BRCAm EOC 
patients, as it is ongoing in some trial (Table 3).
Furthermore, Higuchi et  al. [101] used an immuno-
competent BRCA1-deficient murine EOC model to com-
pare treatment with Cytotoxic T Lymphocyte-associated 
Antigen-4 (CTLA-4) or PD-1/PD-L1 antibodies alone or 
combined with targeted cytotoxic therapy using a PARPi. 
Correlative studies were performed in vitro using human 
BRCA1(−) cells. They found that CTLA-4 antibody, but 
not PD-1/PD-L1 blockade, synergized therapeutically 
with the PARPi, resulting in immune-mediated tumor 
clearance and long-term survival in a majority of animals 
(P < 0.0001). These results support clinical testing of this 
regimen to improve outcomes for women with BRCAm 
EOC.
Actually, there are many trials in progress to address 
the additional populations that may have deficiencies in 
the HR pathway that will benefit from PARPi (Table  3). 
Additionally, combination trials with chemotherapy, radi-
ation and TKIs are expanding the exploration of usage. 
Suggested by the cediranib and olaparib combination, 
combining PARPi with another agent may not require 
additional DNA impairment for efficacy. Trials are also 
underway investigating agents that impair the DNA dam-
age repair pathway, like veliparib and dinaciclib creating 
synthetic lethality without additional patient selection 
[102] (Table 3).
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Table 3 PARP inhibitors in ovarian cancer—phase II–III ongoing studies
ClinicalTrials.gov  
Identifier
Responsible  
party
Ph Drugs
NCT01033292 Sanofi II CBDC/GEM with INI in Pts with platinum-resistant recurrent EOC
NCT01033123 Sanofi II CBDC/GEM with INI in Pts with platinum-sensitive recurrent EOC
NCT00677079 Sanofi II INI in Pts with BRCA-1 or BRCA-2 associated advanced EOC
NCT01482715 Clovis Oncology, Inc. II RUC in Pts with gBRCA Mutation EOC
NCT01891344 Clovis Oncology, Inc. II RUC in Pts with platinum-sensitive, relapsed, HGSOC (ARIEL2)
NCT01968213 Clovis Oncology, Inc. III RUC as switch maintenance after platinum in relapsed HGSOC (ARIEL3)
NCT00664781 Cancer Research UK II RUC in known carriers of a BRCA 1 or BRCA 2 mutation with advanced EOC
NCT01690598 Vejle Hospital II VEL and TOP for Pts with platinum-resistant or partially platinum-sensitive 
relapse of EOC with negative or unknown BRCA status
NCT01472783 Vejle Hospital II VEL for Pts with BRCA germline mutation and platinum-resistant or partially 
platinum-sensitive relapse of EOC
NCT01113957 AbbVie (Abbott) II VEL with TEM vs PLD alone in subjects with recurrent HGSOC
NCT01306032 National Cancer Institute II VEL in combination with metronomic oral CYC in refractory BRCA-positive 
EOC
NCT02470585 AbbVie III CBDC/P with or without concurrent and continuation maintenance VEL in 
subjects with previously untreated stages III or IV HGSOC
NCT01540565 National Cancer Institute II VEL in persistent or recurrent EOC with germline BRCA1/BRCA2 mutation
NCT02392676 AstraZeneca III PLA controlled study of OLA maintenance in Pts With platinum sensitive 
relapsed EOC and loss of function somatic BRCA mutation(s) or loss of 
function mutation(s) in tumour homologous recombination repair-
associated genes
NCT01874353 AstraZeneca III PLA controlled study of OLA maintenance in platinum sensitive relapsed 
BRCA mutated EOC Pts with a complete or partial response following 
platinum based CT
NCT02571725 New Mexico Cancer Care Alliance II Combination of OLA and TREM, in BRCA1 and BRCA2 mutation carriers with 
recurrent EOC
NCT01844986 AstraZeneca III OLA maintenance in Pts With BRCA mutated advanced EOC following first 
line platinum based CT
NCT01081951 AstraZeneca III OLA With P and CBDC vs P and CBDC alone in Pts with platinum sensitive 
advanced EOC
NCT02503436 AstraZeneca II OLA treated BRCAm EOC POPULATION
NCT02282020 AstraZeneca III OLA vs Physician’s choice single agent CT for platinum sensitive relapsed 
EOC in Pts carrying germline BRCA1/2 mutations
NCT02484404 National Institutes of Health Clinical 
Center (National Cancer Institute)
II Anti-programmed death ligand-1 antibody MEDI4736 in combination With 
OLA or CED for advanced solid tumors and advanced or recurrent EOC
NCT02340611 University Health Network, Toronto II Combination CED-OLA at the time of disease progression on OLA in EOC
NCT01661868 Ursula A. Matulonis, MD, Dana-Farber 
Cancer Institute
II OLA for Pts with recurrent BRCA deficient EOC with no prior PARP exposure 
or prior PARP inhibitor exposure
NCT02477644 ARCAGY/GINECO GROUP III OLA or PLA in with platinum-taxane and BV and as maintenance therapy
NCT02345265 National Cancer Institute II OLA and CED for the treatment of recurrent EOC
NCT02208375 M.D. Anderson Cancer Center II OLA With AZD2014 or AZD5363 for recurrent endometrial, triple negative 
breast, and ovarian, primary peritoneal, or fallopian tube cancer
NCT02502266 National Cancer Institute II/III CED and OLA compared to CED or OLA alone, or standard of care CT in 
women with recurrent platinum-resistant or -refractory EOC
NCT02489006 University Health Network, Toronto II OLA in Pts with platinum sensitive recurrent HGSOC
NCT00628251 AstraZeneca II OLA vs intravenous liposomal doxorubicin given monthly in Pts with 
advanced BRCA1- or BRCA2-associated EOC who have failed previous 
platinum-based CT
NCT02485990 Sidney Kimmel Comprehensive Cancer 
Center
II TREM alone or combined with OLA for recurrent or persistent EOC
NCT01116648 National Cancer Institute II CED and OLA for recurrent papillary-serous ovarian, fallopian tube, or peri-
toneal cancer or for treatment of recurrent TNBC
NCT01078662 AstraZeneca II OLA in Pts with advanced cancers BRCA 1 and/or BRCA2 mutation
NCT00494442 AstraZeneca II OLA twice daily in Pts with advanced BRCA1 or BRCA2 associated EOC
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Therefore, the approval of olaparib in the maintenance 
setting in Europe and metastatic setting in the US for 
patients with deleterious BRCAm in EOC is just the tip 
of the iceberg for the utilization for this class of agents.
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